加载中
NASDAQHealthcareBiotechnology
最新数据
US$10.05
−US$0.47 · -4.47%
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
收盘时
US$10.05
−US$0.47 · -4.47%
盘后
US$10.05
US$0.00 · 0.00%
10月12日 16:15 ET
盘中时间采用ET。市场数据可能有所延迟。
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
日内区间
当前US$10.05
52周区间
当前US$10.05
盘中时间采用ET。市场数据可能有所延迟。
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
日内区间
当前US$10.05
52周区间
当前US$10.05
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 10.5万 USD | — | — | — | — |
| 毛利 | −10.5万 USD | — | — | — | — |
| 研究与开发 | 3371.9万 USD | 1938.5万 USD | 1652.6万 USD | 2446.8万 USD | 2911.5万 USD |
| 销售、一般及管理费用 | 925.2万 USD | 816.3万 USD | 688.1万 USD | 809.7万 USD | 951.5万 USD |
| 营业费用 | 4286.6万 USD | 2754.8万 USD | 2340.7万 USD | 3256.5万 USD | 3863万 USD |
| 利息收入 | 250.5万 USD | 182.4万 USD | 158.4万 USD | 65.4万 USD | — |
| 利息支出 | — | — | — | — | 1.5万 USD |
| 折旧和摊销 | 10.5万 USD | 8.5万 USD | 15.1万 USD | 36.7万 USD | 46万 USD |
| 营业利润 | −4297.1万 USD | −2754.8万 USD | −2340.7万 USD | −3256.5万 USD | −3863万 USD |
| 净利润 | −1528.3万 USD | −6229.3万 USD | −2702.9万 USD | −4130.7万 USD | −4324.1万 USD |
公司数据更新于 2026年10月12日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$40.00
上涨空间 298.01%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3379.53万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1876.39万0.19%98.74亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1759.58万0.02%787.4亿 USD0.19%US$277.88-0.38%
Vanguard Extended Market ETFVXF1209.4万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO620.44万0.04%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO546.14万0.03%180亿 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB522.83万0.05%108.2亿 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA405.37万0.02%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
